• Trevi Therapeutics recently reported that key results from its Phase 2b CORAL trial of oral nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis have been published in the Journal of the American Medical Association, showing statistically significant reductions in 24-hour cough frequency and a safety profile consistent with prior studies.
• Over 60% of treated patients achieving at least a 50% reduction in cough frequency by Week 6 underscores the therapy’s potential to address a difficult-to-treat symptom in a serious lung disease.
• We’ll now examine how the JAMA publication of nalbuphine ER’s Phase 2b efficacy and safety data could shape Trevi Therapeutics’ investment narrative.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

What Is Trevi Therapeutics' Investment Narrative?

For Trevi Therapeutics, the big picture an investor needs to buy into is that Haduvio (oral nalbuphine ER) can transition from promising trial data to an approved, commercially viable treatment for chronic cough in IPF and potentially other refractory cough settings, before the company’s cash and investor patience run thin. The JAMA publication of the Phase 2b CORAL data strengthens the scientific and clinical credibility of the program, and could become a meaningful short term catalyst if it supports partnering interest or a clear path into later stage trials. That said, Trevi still has no revenue, ongoing losses and a history of shareholder dilution following capital raises, so execution risk remains high even with this positive spotlight on nalbuphine ER.

However, there is a key funding and dilution risk that shareholders should not overlook. The valuation report we've compiled suggests that Trevi Therapeutics' current price could be inflated.

Exploring Other Perspectives

The Simply Wall St Community’s two fair value estimates span US$21.30 to US$35.00 per share, showing how far apart personal models can be. Set that against Trevi’s lack of current revenue and ongoing losses, and you can see why it pays to compare several viewpoints before forming your own expectations.

Explore 2 other fair value estimates on Trevi Therapeutics - why the stock might be worth over 3x more than the current price!

Build Your Own Trevi Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Trevi Therapeutics research is our analysis highlighting 3 important warning signs that could impact your investment decision.
• Our free Trevi Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Trevi Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 32 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.